Summary & Overview

HCPCS G9830: Her-2/neu Positive Status

HCPCS Level II code G9830 denotes documented Her-2/neu positive status, a key tumor biomarker used to guide oncology diagnosis and treatment decisions nationally. As a reporting code for HER2 positivity, G9830 conveys clinically actionable information that influences therapeutic selection, particularly targeted therapies in breast and certain gastric cancers, and affects downstream care pathways and utilization.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, common sites where the status is documented (pathology and clinical laboratories), and what to expect when the code appears on claims and reports. The publication summarizes benchmark and policy considerations relevant to national reimbursement and billing practice, highlights how HER2 status reporting integrates with oncology care, and points to areas where coding clarity affects claims processing.

This summary provides clinicians, coding professionals, and policy analysts with the essential context for G9830, including its role in clinical decision-making, payer relevance, and the types of information and documentation typically associated with the code. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9830HCPCS Level IIHER2oncologypathologylaboratorybiomarkercancer-testing

Billing Code Overview

HCPCS Level II code G9830 indicates Her-2/neu positive. This code denotes a documented positive status for the human epidermal growth factor receptor 2 (HER2/neu), a tumor biomarker commonly used in oncology to characterize certain breast and gastric cancers. The service type associated with this code is biomarker/status reporting, reflecting the result of laboratory or pathology testing that identifies HER2/neu positivity.

The typical site of service for documentation of HER2/neu positive status is pathology or clinical laboratory settings, including hospital laboratories, independent reference labs, and pathology departments where tumor specimens are analyzed and results are reported.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 52-year-old woman recently diagnosed with invasive ductal carcinoma of the breast on core needle biopsy. Immunohistochemical testing or fluorescence in situ hybridization identifies the tumor as Her-2/neu positive. The specimen is processed in a hospital or independent pathology laboratory and the result is reported to the treating medical oncologist and surgical team. The clinical workflow includes receipt of tissue from surgery or biopsy, histologic confirmation, performance of HER2 testing (IHC and/or FISH), pathology interpretation, generation of a pathologist report including HER2 status, and transmission of results to the oncology care team to guide targeted therapy decisions such as trastuzumab.

Typical site of service: hospital outpatient pathology laboratory or independent clinical laboratory; specimen may originate from an outpatient surgical center, hospital inpatient setting, or office-based biopsy procedure.

Typical patient scenario modifiers: complexity of interpretation or additional technical services may require modifiers such as 22 for increased procedural services when the pathologist documents substantial additional work, or 52/53 for reduced or discontinued services if testing cannot be completed due to inadequate specimen. Other operational modifiers may reflect anesthesia or staffing but are less commonly applied to laboratory-only services.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the pathologist documents substantial additional work beyond the typical service for HER2 interpretation, with supporting documentation.
`23`	Unusual anesthesia	Not routinely used for laboratory HER2 testing; may apply if anesthesia was required for the diagnostic procedure (e.g., biopsy) billed separately.
`52`	Reduced services	Use when HER2 testing is partially performed or scope is reduced from the full procedure.
`53`	Discontinued procedure	Use when testing is started but discontinued due to specimen unsuitability or technical failure.
`54`	Surgical care only	Not typically applicable to standalone lab testing; may apply to the surgeon when only surgical portion is billed separate from postoperative care.
`55`	Postoperative management only	Not typically applicable to pathology reporting; used for physicians providing only post-op care.
`56`	Preoperative management only	Rare for pathology; may apply to clinicians who only performed preoperative evaluation related to the procedure.
`62`	Two surgeons	Use when two surgeons of different specialties actively participate in the surgical procedure that yielded the specimen; not for the lab test itself.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Not typically used for laboratory HER2 testing; applicable to perioperative billing.
`CO`	Chargeable to worker's compensation	Use when the service is billed to a worker's compensation payer.
`CQ`	Service furnished under a clinical research study, non-covered item or service	Use when HER2 testing is provided as part of a clinical trial and payor requires identification.
`FX`	Primary surgeon	Use in operative claims when identifying the primary surgeon; not used on laboratory claims.
`FY`	Assistant surgeon	Use in operative claims when an assistant surgeon is billed; not used on laboratory claims.
`QK`	Medical direction of two, three, or four assistants	Operative modifier; not used for laboratory services but included when surgical team billing is present.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Anatomic Pathology	Pathologists who perform histopathologic evaluation and HER2 interpretation.
`207QA0002X`	Clinical Pathology	Laboratory pathologists responsible for immunohistochemistry and molecular testing.
`364S00000X`	Hematology/Oncology	Medical oncologists who use HER2 results to plan systemic therapy.
`208800000X`	General Surgery	Surgeons who obtain tissue via biopsy or resection; bill surgical services.
`261QP0200X`	Medical Laboratory Technologist/Technician	Laboratory professionals who perform IHC or FISH testing under supervision.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.911`	Malignant neoplasm of unspecified site of right female breast	Primary breast cancer diagnosis prompting HER2 testing to determine targeted therapy eligibility.
`C50.912`	Malignant neoplasm of unspecified site of left female breast	Left-sided breast cancer requiring HER2 status for treatment planning.
`C50.111`	Malignant neoplasm of central portion of right female breast	Tumor location codes paired with HER2 testing for staging and therapy decisions.
`C50.121`	Malignant neoplasm of central portion of left female breast	Tumor location codes paired with HER2 testing for staging and therapy decisions.
`D05.11`	Lobular carcinoma in situ of right breast	In-situ lesions sometimes undergo receptor testing in select clinical circumstances.
`D05.12`	Lobular carcinoma in situ of left breast	In-situ lesions sometimes undergo receptor testing in select clinical circumstances.
`Z85.3`	Personal history of malignant neoplasm of breast	Relevant when HER2 testing is performed for recurrence assessment or new lesion evaluation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`88342`	Immunohistochemistry, each antibody stain	Commonly used for reporting HER2 testing by IHC when the lab performs an antibody stain for HER2 protein expression; may be billed per stain.
`88377`	Morphometric analysis; computer-assisted image analysis of immunohistochemistry	Used when image analysis quantitation of HER2 IHC is performed to assist scoring.
`88367`	Immunohistochemistry or immunocytochemistry, per specimen; interpretation and report	Sometimes used for reporting interpretation of IHC panels; adjunct to technical staining codes.
`88374`	Special stains, each additional (e.g., FISH preparation)	May be used for special preparation steps related to FISH or other cytogenetic preparations.
`88384`	Flow cytometry interpretation	Not routinely used for HER2 testing but included when ancillary testing is performed for concurrent hematologic concerns.